I am delighted to welcome you all for Twenty Third Annual General Meeting. This is thefirst AGM after the Initial Public Offer (IPO) and listing of Shares on SME Platform ofBSE Ltd.We must record our sincere thanks and appreciation to all those who applied in ourIPO and have stood by us with their investments. Your continued trust encouragementsupport and fair criticism based on data and facts are what give us energyenthusiasm confidence and motivation to strive for betterment)
Your Company believes in 'Quality and Timely Delivery" and these have beenpillars of our Success in the National and International Markets. The combination ofoperational excellence and improved quality were the key drivers of our Company whichresulted in improved profitability.
Your Company Bajaj Healthcare Limited is a backward ante grated pharmaceuticalcompany with manufacturing and marketing capabilities in Active Pharmaceutical Ingredients(APIs) Intermediates and Finished Dosage Formulations (PDFs) with focus on VitaminsAmino Acids Anti-Con valiant and Finished Dosage Forms (PDFs) catering to varioustherapeutic segments.
Your Company has State - of - the - Art manufacturing and R&D facilities which willhelp us to make further inroads in highly regulated and challenging markets. BajajHealthcare has always been on the right side of the stringent regulatory audits and hasfollowed processes recommended by various regulators thereby constantly upgrading byimplementing and adopting cGMP
Your Company began its operations in the year 1993 with an API manufacturing unit inTarapur near Mumbai Over the years we have expanded our scale and scope of operationsand currently we have enlarged our wings up to five (5) manufacturing units lormanufacture of APIs Intermediates and Formulations. As part of this expansion in theyear 2006 we acquired a 46000 sq. mtrs. plant in Savii Vadodara for selling up one ofour biggest API and Inlcrmedialc manufacturing units. In the year 2008 with a view toenter into manufacturing of PDFs we acquired a 3000 sq; mtrs. Formulations plant atManjusar Vadodara and we have converted it into a state-of-the-art WHO-GMP compliantfacility. Keeping in momentum of die expansion in the year 2013 we set-up yet anotherAPI and Intermediate manufacturing unit at Panoli Ankleshwar In the last fiscal ie. inF Y. 14-15 with the growing demand for APIs we decided to have a separate unit forIntermediate products so that die Savii and Panoli Units could concentrate on manufactureof APIs. Accordingly in November 20 M we acquired and sc (-up an Intermediate Unit inTarapur MIDC near Mumbai.
Your Company's Sales/Income born operation (Gross) stood at Rs. 22321 .SILakhs ascompared to Rs. 21837.63 lakhs in the Previous Year. Net Profit Aftci Tax Cor the Cuneuiyear is Rs. 820.03 Lakhs as compared to previous year's Rs. 751.21 Lakhs..
In conclusion I would like to thank all our .Stakeholders and Boards members for theircontinued trust; guidance and Support. I am also grateful to four Customers VendorsBankers and Other Business Associates who have reposed their faith in us. I would alsolike to extend my appreciation to our employees for their commitment and contribution inour Company.
We remain focus about our future with a well balanced strategy and determination tomake the most of the available opportunities thereby creating greater value for all ourStakeholders
Chairman & Managing Director